Literature DB >> 16569433

Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients.

Belén Ramos1, Marina Núñez, Carlos Toro, Julie Sheldon, Javier García-Samaniego, Pilar Ríos, Vincent Soriano.   

Abstract

BACKGROUND: Changes in the prevalence of distinct hepatitis C virus (HCV) genotypes and subtypes over time have not been explored in detail.
METHODS: A retrospective analysis was carried out in all specimens from subjects with chronic hepatitis C sent for testing to a reference laboratory in Spain since 1998-2004.
RESULTS: A total of 1226 distinct subjects were analyzed. The most frequent HCV genotype was 1 (64.1%), followed by 3 (20.9%) and 4 (11.7%). The most frequent HCV subtype was 1b (32.4%). A total of 797 patients (65%) were HIV-positive. Although genotype 1 was the most frequent, it represented 74.6% of HIV-negative and 58.5% of HIV-positive patients (p<0.01). While HCV subtype 1a was the most frequent among HIV-positive subjects (32.1%), 1b was the most common in HIV-negative patients (53.8%). There was a significant increase in the prevalence of genotype 4 and conversely a decline in genotype 3 among HIV-positive patients over time.
CONCLUSION: Genotype 1 is the most frequent HCV variant circulating in Spain. Genotypes 3 and 4 are significantly more prevalent in HIV/HCV-coinfected than in HCV-monoinfected patients. However, HCV-3 has declined and HCV-4 is increasing in the former group. These findings are relevant given their different susceptibility to interferon-based therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16569433     DOI: 10.1016/j.jinf.2006.02.006

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  9 in total

1.  New perspectives in occult hepatitis C virus infection.

Authors:  Vicente Carreño; Javier Bartolomé; Inmaculada Castillo; Juan Antonio Quiroga
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

2.  Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.

Authors:  Daryoush Behzadpour; Abbas Ahmadi Vasmehjani; Seyed Dawood Mousavi Nasab; Nayeb Ali Ahmadi; Rasoul Baharlou
Journal:  Pathog Glob Health       Date:  2016-11-10       Impact factor: 2.894

3.  Change in hepatitis C virus clades: a cross-sectional study of chronic HCV patients in Pakistan from 2000-2010.

Authors:  S Butt; M Idrees; M Shahid; I Amin; S Younas; S Afzal; H Akbar; I Ur Rehman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-06       Impact factor: 3.267

4.  Co-infection by hepatitis C virus in HIV-infected patients in southern Brazil: genotype distribution and clinical correlates.

Authors:  Fernando H Wolff; Sandra C Fuchs; Nêmora N T Barcellos; Paulo Ricardo de Alencastro; Maria Letícia R Ikeda; Ajácio B M Brandão; Maicon Falavigna; Flávio D Fuchs
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

5.  Changing pattern of clinical epidemiology on hepatitis C virus infection in southwest china.

Authors:  Zehui Yan; Ke Fan; Yuming Wang; Yi Fan; Zhaoxia Tan; Guohong Deng
Journal:  Hepat Mon       Date:  2012-03-28       Impact factor: 0.660

6.  Association of laboratory parameters with viral factors in patients with hepatitis C.

Authors:  Bushra Ijaz; Waqar Ahmad; Fouzia T Javed; Sana Gull; Muhammad T Sarwar; Humera Kausar; Sultan Asad; Shah Jahan; Saba Khaliq; Imran Shahid; Aleena Sumrin; Sajida Hassan
Journal:  Virol J       Date:  2011-07-21       Impact factor: 4.099

7.  HCV genotype-specific correlation with serum markers: higher predictability for genotype 4a.

Authors:  Waqar Ahmad; Bushra Ijaz; Fouzia T Javed; Humera Kausar; Muhammad T Sarwar; Sana Gull; Sultan Asad; Imran Shahid; Sajida Hassan
Journal:  Virol J       Date:  2011-06-10       Impact factor: 4.099

8.  Epidemiological features of patients infected with HCV genotype 4 in Poland: Epidemiology of HCV genotype 4 in Poland.

Authors:  Slawomir Chlabicz; Robert Flisiak; Tadeusz W Lapinski; Oksana Kowalczuk; Alicja Wiercinska-Drapalo; Barbara Pytel-Krolczuk; Anna Grzeszczuk; Lech Chyczewski; Joanna Pancewicz
Journal:  Hepat Mon       Date:  2011-03       Impact factor: 0.660

Review 9.  Public Health Considerations among People who Inject Drugs with HIV/HCV Co-Infection: A Review.

Authors:  Rachel M Murdock; Marisa B Brizzi; Omar Perez; Melissa E Badowski
Journal:  Infect Dis Ther       Date:  2019-01-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.